logo-loader
viewe-Therapeutics plc

Full interview: e-Therapeutics’ Barlow hails deals with Novo Nordisk and ‘top five pharma company’

Ray Barlow, chief executive of e-Therapeutics (LON:ETX), talks to Proactive’s Andrew Scott about the company’s unique approach to drug discovery, which uses computational techniques to find potential breakthrough new treatments.

He also provided some insight into recent tie-ups with Denmark’s Novo Nordisk and an unnamed ‘top five pharma company’. 

Quick facts: e-Therapeutics plc

Price: 3.05 GBX

AIM:ETX
Market: AIM
Market Cap: £8.2 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of e-Therapeutics plc named herein, including the promotion by the Company of e-Therapeutics plc in any Content on the Site, the Company receives...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

e-Therapeutics continuing to convert business development into cash...

e-Therapeutics PLC's (LON:ETX) Ray Barlow says they're actively engaged in exploring all organic and non-organic opportunities that have the potential to create incremental value for its shareholders. He adds that multiple proposals for its artificial intelligence-based drug research products...

on 7/10/19

RNS

Holding(s) in Company

1 week, 5 days ago

Holding(s) in Company

3 weeks, 1 day ago

Holding(s) in Company

3 weeks, 2 days ago

Holding(s) in Company

3 weeks, 2 days ago

Holding(s) in Company

3 weeks, 2 days ago

Half-year Report

on 7/10/19

2 min read